COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

Covid19 Clinical Trial

Official title:

Prospective, Open-Label Single Ascending Dose Study of Two Dose Levels of Frunexian (EP-7041), Followed by a Randomized Comparison of One Dose With Institutional Standard Care, for Thromboprophylaxis in Patients Managed in Intensive Care Settings for COVID-19 Syndrome: The COVID-ThromboprophylaXIs Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05040776
• Other study ID #: 2020-eXIthera-Prophy-001
• Status: Withdrawn
• Phase: Phase 2
• Start date: October 2023
• Est. completion date: May 2025

Study information

• Verified date: October 2023
• Source: eXIthera Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19 syndrome who based on clinical judgment require care in an intensive care unit, regardless of whether or not mechanical ventilation is in use or is anticipated. Patients should be enrolled on the first day of the ICU stay; withdrawal of prior thromboprophylaxis, if any, will follow specific protocol guidance. Enrolled patients will thereafter be administered intravenous frunexian (EP-7041) until disposition from the hospital (including post-ICU non-critical care management)

Description:

The goal of the COVID-ThromboprophylaXIs Study is to determine the safety and tolerability of two doses of frunexian (EP-7041) for the prevention of thromboembolism in the management of COVID-19 patients, compared to control patients managed with institutional standard care thromboprophylaxis regimens. Dosing of frunexian for the first 15 patients enrolled will be randomized to 0.6 mg/kg/hr IV (n=15) and next 15 patients will be randomized to 1.0 mg/kg/hr IV (n=15) for the duration of the index hospitalization. Enrollment will be paused after treatment of these 30 patients, at which time a dedicated DSMB will evaluate all collected safety data through 7 days post-index hospital discharge. If no adverse safety signal is identified for the 1.0 mg/kg/hr dose, enrollment will be resumed with the study dose of frunexian randomized 2:1 to 1.0 mg/kg/hr or institutional standard care for thromboprophylaxis in ICU patients with COVID-19. If safety concerns are identified for the higher dose and not for the lower dose, then open-label randomized enrollment vs institutional standard of care for thromboprophylaxis will proceed with an frunexian dose of 0.6 mg/kg/hr. The second phase of the study will enroll 60 additional patients, with 40 in the frunexian dosing arm, and 20 in the standard care arm.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2025
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• SARS-CoV-2 test (by local evaluation) positive

• Symptom severity and general risk of decompensation warrants, in the opinion of the treating clinician, admission to/care in an intensive care unit setting

• Patient or legally authorized representative (LAR) able and willing to provide written informed consent

• No contraindication to receiving anticoagulation

• At least one D-dimer value =2 times local ULN (within 72 hours of hospital admission)

Exclusion criteria

Patients who meet ANY of the following criteria are not eligible for inclusion:

• Moribund patient not expected to survive 24 hours

• ICU length of stay > 24 hours prior to initiation of frunexian infusion

• Existing venous thromboembolism

• Known immune compromise (HIV/AIDS, chemotherapy, chronic corticosteroid therapy, transplant patient, etc.)

• Active cancer diagnosis

• Pregnant, lactating, or parturient woman

• bodyweight <40kg

• hemoglobin <8.0 g/L in the last 72 hours

• platelet count <50 x 109/L in the last 72 hours

• known fibrinogen <1.5 g/L (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation)

• known INR >1.8 (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation)

• patient already on therapeutic anticoagulation at the time of screening (low or high dose nomogram UFH, LMWH, warfarin, or any regular dose of a direct oral anticoagulant)

• patient on dual antiplatelet therapy, when at least one of the agents cannot be stopped safely

• history of spontaneous intracranial bleeding; gastrointestinal bleeding requiring hospitalization and/or transfusion within prior 3 months

• major surgery within prior 30 days

• known bleeding within the last 30 days requiring emergency department presentation or hospitalization

• known history of a bleeding disorder of an inherited or active acquired bleeding disorder

• recent (<48 hours) or planned spinal or epidural anesthesia or puncture

• anticipated transfer to another hospital that is not a study site within 72 hours

• enrollment in other trials related to anticoagulation or antiplatelet therapy

• use of pneumatic compression devices for thromboprophylaxis

• Failure to meet ALL Inclusion Criteria

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Thrombocytopenia
• Thrombopenia

Intervention

Drug:
• EP-7041 Injection
EP-7041 infusion

Locations

Country	Name	City	State
United States	VA Greater Los Angeles Healthcare System	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
eXIthera Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Identify the appropriate dose of EP-7041 that demonstrates safety as defined by incidence of treatment-emergent adverse events	30 days after discharge